Institute of Internal Medicine and Geriatrics, Università Cattolica del Sacro Cuore, 00168, Rome, Italy.
Fondazione Policlinico Universitario "Agostino Gemelli"-IRCSS, Largo A Gemelli, 8, 00168, Rome, Italy.
Aging Clin Exp Res. 2020 Jul;32(7):1369-1373. doi: 10.1007/s40520-020-01469-4. Epub 2020 Jan 24.
Safinamide, as a levodopa adjunct, is effective in reducing motor fluctuations in Parkinson's disease (PD) patients; however, scarce evidence is available regarding its use in older PD patients.
To evaluate the safety and tolerability of safinamide as an adjunct therapy in patients aged ≥ 60 years with advanced PD.
A retrospective study including 203 PD patients admitted to a geriatric day hospital, who were evaluated following an extensive clinical protocol. Safinamide use was categorized as never used, ongoing, and withdrawn. Potential correlations of Safinamide withdrawal were investigated in stepwise backward logistic regression models.
A total of 44 out of 203 participants were current or former users of Safinamide. Overall, 14 (32%) patients discontinued due to treatment-emergent adverse events (TEAEs). Withdrawal was not associated with older age.
Safinamide as an adjunct therapy in patients aged ≥ 60 years with advanced PD was found to be safe and well-tolerated in older patients. There were no specific demographic or clinical characteristics associated with suspension.
作为左旋多巴辅助用药，氨磺必利在减少帕金森病（PD）患者的运动波动方面有效；然而，关于其在老年 PD 患者中的应用，证据有限。
评估氨磺必利作为辅助治疗在年龄≥60 岁的晚期 PD 患者中的安全性和耐受性。
一项回顾性研究纳入了 203 名入住老年日间医院的 PD 患者，他们根据广泛的临床方案进行了评估。将氨磺必利的使用分为从未使用、正在使用和已停用。采用逐步向后逻辑回归模型探讨了氨磺必利停药的潜在相关性。
203 名参与者中共有 44 名是氨磺必利的现用或曾用者。总体而言，由于治疗中出现的不良事件（TEAEs），14 名（32%）患者停药。停药与年龄较大无关。
在年龄≥60 岁的晚期 PD 患者中，作为辅助治疗的氨磺必利在老年患者中被发现是安全且耐受良好的。没有与停药相关的特定人口统计学或临床特征。
